Recombinant human growth hormone (r-hGH)
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Infant, Small for Gestational Age
Conditions
Infant, Small for Gestational Age
Trial Timeline
Feb 1, 2004 → Jul 1, 2009
NCT ID
NCT01067352About Recombinant human growth hormone (r-hGH)
Recombinant human growth hormone (r-hGH) is a phase 3 stage product being developed by Merck for Infant, Small for Gestational Age. The current trial status is terminated. This product is registered under clinical trial identifier NCT01067352. Target conditions include Infant, Small for Gestational Age.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01187550 | Approved | Completed |
| NCT01111019 | Phase 2 | Completed |
| NCT01067352 | Phase 3 | Terminated |
Competing Products
20 competing products in Infant, Small for Gestational Age
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| TSHA-101 | Taysha Gene Therapies | Phase 1/2 | 36 |
| somatropin | Eli Lilly | Phase 3 | 77 |
| Placebo + Cisapride | Johnson & Johnson | Approved | 85 |
| RotaTeq (V260) + IPV | Merck | Phase 3 | 77 |
| recombinant somatropin | Merck | Pre-clinical | 23 |
| MAS825 + Placebo | Novartis | Phase 2 | 52 |
| epoetin beta + epoetin beta | Roche | Pre-clinical | 23 |
| Genotropin (PN-180,307) Somatropin + Control-no treatment | Pfizer | Phase 3 | 76 |
| Prevenar (13v) | Pfizer | Pre-clinical | 22 |
| rhBSSL + Placebo | Swedish Orphan Biovitrum | Phase 2 | 51 |
| rhBSSL + Placebo | Swedish Orphan Biovitrum | Phase 2 | 51 |
| DT5aP-IPV-Hib 5-component Pertussis vaccine + DT3aP-HBs-IPV | Sanofi | Phase 3 | 76 |
| alglucosidase alfa + alglucosidase alfa | Sanofi | Approved | 84 |
| Myozyme | Sanofi | Phase 2 | 51 |
| Bacillus Clausii Multi ATB Resist + Placebo | Sanofi | Approved | 84 |
| Radiprodil | UCB | Phase 2 | 49 |
| Larotrectinib (Vitrakvi, BAY2757556) + Standard of Care | Bayer | Pre-clinical | 20 |
| Sabril® | Lundbeck | Pre-clinical | 20 |
| Vigabatrin | Lundbeck | Approved | 82 |
| Nusinersen | Biogen | Pre-clinical | 20 |